[go: up one dir, main page]

AR121611A2 - Inhibidores de glucosilceramida sintasa - Google Patents

Inhibidores de glucosilceramida sintasa

Info

Publication number
AR121611A2
AR121611A2 ARP210100682A ARP210100682A AR121611A2 AR 121611 A2 AR121611 A2 AR 121611A2 AR P210100682 A ARP210100682 A AR P210100682A AR P210100682 A ARP210100682 A AR P210100682A AR 121611 A2 AR121611 A2 AR 121611A2
Authority
AR
Argentina
Prior art keywords
hemitartrate
formula
glucosylceramide synthase
synthase inhibitors
disclosed
Prior art date
Application number
ARP210100682A
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR121611(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR121611A2 publication Critical patent/AR121611A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se desvela la sal de hemitartrato de un compuesto representado por la siguiente fórmula estructural (1) (Hemitartrato de fórmula (1)), que puede utilizarse en aplicaciones farmacéuticas. Las formas cristalinas únicas particulares de Hemitartrato de fórmula (1) se caracterizan por una variedad de propiedades y mediciones físicas. También, se desvelan métodos para producir Hemitartrato cristalino de fórmula (1), y utilizarlo para inhibir glucosilceramida sintasa o reducir las concentraciones de glicoesfingolípidos en sujetos para tratar un número de enfermedades. También se describen las composiciones farmacéuticas.
ARP210100682A 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa AR121611A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
AR121611A2 true AR121611A2 (es) 2022-06-22

Family

ID=43431870

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP100104348A AR079152A1 (es) 2009-11-27 2010-11-24 Inhibidores de glucosilceramida sintasa
ARP210100683A AR121612A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa
ARP210100682A AR121611A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP100104348A AR079152A1 (es) 2009-11-27 2010-11-24 Inhibidores de glucosilceramida sintasa
ARP210100683A AR121612A2 (es) 2009-11-27 2021-03-18 Inhibidores de glucosilceramida sintasa

Country Status (40)

Country Link
US (6) US11458119B2 (es)
EP (5) EP2796457B1 (es)
JP (6) JP2013512252A (es)
KR (6) KR20120115972A (es)
CN (5) CN105777707B (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA3075788C (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK3133070T3 (es)
DO (2) DOP2012000141A (es)
EA (3) EA029990B1 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2586947T3 (es)
GT (1) GT201200161A (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE045784T2 (es)
IL (4) IL310635A (es)
LT (2) LT3133070T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (2) MX381242B (es)
MY (2) MY160542A (es)
NI (1) NI201200096A (es)
NZ (3) NZ625712A (es)
PE (2) PE20171255A1 (es)
PH (2) PH12015502514B1 (es)
PL (4) PL3599237T3 (es)
PT (4) PT3133070T (es)
RS (3) RS59543B1 (es)
SG (2) SG10201407881WA (es)
SI (3) SI2796457T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI656873B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
BR112012012947B8 (pt) 2009-11-27 2021-05-25 Genzyme Corp sal de hemitartarato e composição farmacêutica compreendendo o mesmo
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP3679923B1 (en) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
DK2968479T3 (da) 2013-03-14 2019-08-12 Icahn School Med Mount Sinai Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
JP6537500B2 (ja) * 2013-09-20 2019-07-03 ビオマリン プハルマセウトイカル インコーポレイテッド 疾患治療用のグルコシルセラミドシンターゼ阻害剤
EP3164128A4 (en) * 2014-07-03 2018-02-28 Dr. Reddy's Laboratories Ltd. Amorphous form of eliglustat hemitartarate
EP3283483B1 (en) 2015-04-14 2018-12-19 Sandoz AG Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6895963B2 (ja) 2015-11-18 2021-06-30 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
MX381953B (es) 2016-02-25 2025-03-13 Asceneuron S A Sales de derivados de piperazina obtenidas por adicion de acidos.
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
BR112019026483A2 (pt) * 2017-06-16 2020-07-14 Beta Pharma, Inc. formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
EP4647130A2 (en) * 2017-08-08 2025-11-12 Amneal Pharmaceuticals LLC Pharmaceutical composition comprising eliglustat
CN111479591A (zh) 2017-12-15 2020-07-31 建新公司 治疗戈谢病的方法
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
AU2019276882A1 (en) * 2018-05-27 2021-01-14 Bioasis Technolgies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
JP2024525229A (ja) * 2021-07-05 2024-07-10 エースニューロン・ソシエテ・アノニム グリコシダーゼインヒビターを含む医薬
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
EP1008342A3 (en) 1994-02-02 2004-12-29 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
JP3850437B2 (ja) 1994-06-10 2006-11-29 生化学工業株式会社 ２−アシルアミノプロパノール化合物及び医薬組成物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) * 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
ATE358473T1 (de) 1998-07-27 2007-04-15 Univ Johns Hopkins Diamino-propanol-verbindungen zur behandlung von ischaemien
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1196406A1 (en) * 1999-07-09 2002-04-17 The Regents of the University of Michigan Amino ceramide-like compounds and therapeutic methods of use
CZ20022332A3 (cs) * 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
PT1475093E (pt) 2000-04-24 2006-11-30 Teva Pharma Hemitartarato de zolpidem micronizado
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004525621A (ja) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
BR122015016313B8 (pt) 2001-07-16 2021-05-25 Genzyme Corp composto semelhante à ceramida e método de preparar um composto
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
DK2206702T3 (da) 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
JP5302537B2 (ja) 2004-09-17 2013-10-02 ユニバーシティ オブ マサチューセッツ リソソーム酵素欠損症のための組成物およびそれらの使用
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
JP4937129B2 (ja) 2004-10-13 2012-05-23 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ３−［５−クロロ−４−［（２，４−ジフルオロベンジル）オキシ］−６−オキソピリミジン−１（６ｈ）−イル］−ｎ−（２−ヒドロキシエチル）−４−メチルベンズアミドの結晶形
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
US20080293946A1 (en) * 2005-10-03 2008-11-27 Cheng Brian K Process for Preparing Zolpidem Hemitartrate and Tartrate Polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
HUE026057T2 (en) * 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX2009007254A (es) * 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
US20100113517A1 (en) * 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
WO2009117122A2 (en) 2008-03-19 2009-09-24 Existence Genetics Llc Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
KR101861981B1 (ko) 2009-11-27 2018-05-28 아드베리오 파마 게엠베하 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
BR112012012947B8 (pt) 2009-11-27 2021-05-25 Genzyme Corp sal de hemitartarato e composição farmacêutica compreendendo o mesmo
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
KR20140033432A (ko) 2011-06-21 2014-03-18 노파르티스 아게 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
HRP20140780T4 (hr) 2021-08-06
EP3133070A1 (en) 2017-02-22
DK2504332T4 (da) 2021-06-07
EP3896069A1 (en) 2021-10-20
DOP2012000141A (es) 2012-09-30
KR20250005503A (ko) 2025-01-09
US12465586B2 (en) 2025-11-11
SG10201407881WA (en) 2015-01-29
JP2019001809A (ja) 2019-01-10
CA3075788C (en) 2021-12-21
PL3133070T3 (pl) 2020-01-31
KR20220162824A (ko) 2022-12-08
MX2012006083A (es) 2012-06-19
KR20120115972A (ko) 2012-10-19
HK1203485A1 (en) 2015-10-30
SI3133070T1 (sl) 2019-11-29
LT2796457T (lt) 2016-09-12
WO2011066352A1 (en) 2011-06-03
HRP20161038T1 (hr) 2016-10-21
TW201639562A (zh) 2016-11-16
LT3133070T (lt) 2019-11-11
US10888547B2 (en) 2021-01-12
DK2796457T3 (en) 2016-08-29
US20130137743A1 (en) 2013-05-30
ECSP12011926A (es) 2012-07-31
EP2504332B1 (en) 2014-06-04
ES2586947T3 (es) 2016-10-19
JP2020189873A (ja) 2020-11-26
US20160120842A1 (en) 2016-05-05
ES2493940T5 (es) 2021-11-23
US20210369672A1 (en) 2021-12-02
ME02477B (me) 2017-02-20
HUE029371T2 (en) 2017-02-28
IL219892A0 (en) 2012-07-31
SI2504332T1 (sl) 2014-09-30
EP2796457B1 (en) 2016-05-18
MA33838B1 (fr) 2012-12-03
ES2875382T3 (es) 2021-11-10
US20230172903A1 (en) 2023-06-08
CL2012001348A1 (es) 2012-08-24
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
AR079152A1 (es) 2011-12-28
NZ715108A (en) 2017-06-30
CN105777707B (zh) 2020-10-13
MX381242B (es) 2025-03-12
SI2796457T1 (sl) 2016-10-28
PT2504332E (pt) 2014-09-02
PL2504332T5 (pl) 2021-08-23
BR112012012947B1 (pt) 2021-04-06
PH12015502514A1 (en) 2016-08-15
JP2016138124A (ja) 2016-08-04
EA201592195A1 (ru) 2016-04-29
PE20171255A1 (es) 2017-08-28
CN102712629B (zh) 2016-10-12
BR112012012947B8 (pt) 2021-05-25
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
ES2754398T3 (es) 2020-04-17
NZ600155A (en) 2014-10-31
CA2781676C (en) 2020-05-05
PL3599237T3 (pl) 2021-09-27
KR20200013105A (ko) 2020-02-05
PL2504332T3 (pl) 2014-10-31
ES2493940T3 (es) 2014-09-12
RS53503B1 (sr) 2015-02-27
JP7150528B2 (ja) 2022-10-11
AU2016202591B2 (en) 2017-11-30
CA2781676A1 (en) 2011-06-03
NI201200096A (es) 2012-10-30
CN112521366A (zh) 2021-03-19
PH12012501048A1 (en) 2013-02-04
HRP20191647T1 (hr) 2019-12-13
IL283935A (en) 2021-07-29
EP3599237A1 (en) 2020-01-29
EA201270646A1 (ru) 2013-01-30
EP2796457A1 (en) 2014-10-29
GT201200161A (es) 2014-01-27
ECSP18063798A (es) 2020-02-28
SMT201600273B (it) 2016-08-31
IL260299A (en) 2018-08-30
EA023923B1 (ru) 2016-07-29
EA029990B1 (ru) 2018-06-29
TWI586663B (zh) 2017-06-11
PT3599237T (pt) 2021-04-28
DOP2016000250A (es) 2017-02-15
UA113491C2 (xx) 2017-02-10
CN112521367A (zh) 2021-03-19
TN2012000237A1 (en) 2013-12-12
IL310635A (en) 2024-04-01
EP3133070B1 (en) 2019-08-14
MY160542A (en) 2017-03-15
US11458119B2 (en) 2022-10-04
DK3133070T3 (da) 2019-11-11
CN102712629A (zh) 2012-10-03
AU2010324810A1 (en) 2012-06-07
CY1115880T1 (el) 2017-01-25
CA3075788A1 (en) 2011-06-03
US20210393590A1 (en) 2021-12-23
PH12015502514B1 (en) 2022-07-29
EP2504332A1 (en) 2012-10-03
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
RS54978B1 (sr) 2016-11-30
AR121612A2 (es) 2022-06-22
SG10201800136QA (en) 2018-02-27
TW201130822A (en) 2011-09-16
PL2796457T3 (pl) 2017-04-28
EA201890254A2 (ru) 2018-10-31
CY1122698T1 (el) 2021-03-12
HUE045784T2 (hu) 2020-01-28
TW201737910A (zh) 2017-11-01
JP2015212291A (ja) 2015-11-26
RS53503B2 (sr) 2021-07-30
CN105753846B (zh) 2019-11-15
CY1117996T1 (el) 2017-05-17
HK1172031A1 (en) 2013-04-12
CN112521367B (zh) 2024-01-02
US20160166542A1 (en) 2016-06-16
HRP20140780T1 (en) 2014-11-07
EP2504332B2 (en) 2021-03-17
JP2023116764A (ja) 2023-08-22
TWI606827B (zh) 2017-12-01
JP2013512252A (ja) 2013-04-11
DK2504332T3 (da) 2014-08-25
EA201890254A3 (ru) 2019-02-28
CA3140959A1 (en) 2011-06-03
AU2017265180A1 (en) 2017-12-14
AU2017265180B2 (en) 2019-08-01
JP6452635B2 (ja) 2019-01-16
JP6370264B2 (ja) 2018-08-08
BR112012012947A2 (pt) 2017-03-01
SI2504332T2 (sl) 2021-08-31
CL2016002589A1 (es) 2017-05-19
CN105777707A (zh) 2016-07-20
KR20150125734A (ko) 2015-11-09
EP3599237B1 (en) 2021-03-24
TWI656873B (zh) 2019-04-21
WO2011066352A8 (en) 2011-08-11
RS59543B1 (sr) 2019-12-31
KR20180049255A (ko) 2018-05-10
PT3133070T (pt) 2019-11-11
MY192644A (en) 2022-08-29
PT2796457T (pt) 2016-07-14

Similar Documents

Publication Publication Date Title
AR121611A2 (es) Inhibidores de glucosilceramida sintasa
UY32062A (es) Inhibidores de beta-secretasa
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
ECSP12011935A (es) Triazolopiridinas
DOP2014000133A (es) Triazolopiridinas sustituidas
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UA107951C2 (xx) Похідні імідазопіридину як інгібітори jak
CO6430426A2 (es) Compuestos de triazolopiridina, y su accion comominhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
ECSP13013011A (es) Triazolopiridinas
DOP2012000312A (es) Triazolopiridinas sustituidas
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
EA201270302A1 (ru) Безводные формы производных пиридина
EA200801893A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве ингибиторов воспаления
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY33584A (es) Nuevos compuestos benzamida de inhibidores lrrk2

Legal Events

Date Code Title Description
FC Refusal